Berlin – In a significant advancement for the treatment of chronic inducible urticaria (CIndU), Novartis has announced positive results from its pivotal Phase III RemIND trial evaluating oral remibrutinib. The study, designed to assess the efficacy and safety of the drug in adults with CIndU who have not adequately responded to H1-antihistamines, met its primary endpoint across three prevalent subtypes: cold urticaria, cholinergic urticaria, and symptomatic dermographism. Notably, patients receiving remibrutinib demonstrated significantly higher complete response rates compared to those receiving a placebo at week 12.
Chronic inducible urticaria is a debilitating condition characterized by hives and swelling triggered by specific stimuli, such as cold, heat, pressure, or exercise. Current treatment options often provide insufficient relief, leaving many patients with a substantial burden on their quality of life. Remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, offers a novel approach by targeting a key pathway involved in the inflammatory response driving these symptoms. The drug works by blocking the release of histamine and other proinflammatory mediators, effectively interrupting the cascade that leads to hives and swelling.
The RemIND trial was a randomized, double-blind, placebo-controlled, multi-center study conducted globally. Its primary outcome measure focused on the proportion of patients achieving complete response at week 12, as determined by provocation tests specific to each CIndU subtype. These provocation tests are designed to reliably reproduce the symptoms in a controlled environment, allowing researchers to objectively assess the drug’s effectiveness. The success across all three tested subtypes underscores the broad potential of remibrutinib in addressing the diverse manifestations of CIndU.
FDA Submission and Future Plans
Following the positive Phase III results, Novartis has already filed a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) specifically for remibrutinib in the treatment of symptomatic dermographism. This submission marks a crucial step towards potentially expanding access to this innovative therapy for patients suffering from this often-debilitating condition. The company plans to submit the complete dataset from the RemIND trial to health authorities worldwide in the coming months, paving the way for potential approvals in other regions. Novartis intends to present the full findings of the RemIND trial at upcoming medical congresses, sharing the data with the broader medical community.
Expert Commentary and Mechanism of Action
Angelika Jahreis, Global Head of Immunology Development at Novartis, emphasized the significance of the RemIND trial results. “The positive RemIND trial results across three different types of CIndU underscore the potential of oral remibrutinib to achieve complete symptom relief for people living with CIndU and build on its recent FDA approval in chronic spontaneous urticaria (CSU),” she stated. “Today’s findings reinforce that remibrutinib could be the first targeted therapy to improve spontaneous and inducible forms of chronic urticaria, helping address a major gap in care for people living with these conditions.”
Remibrutinib’s mechanism of action centers around its selective inhibition of Bruton’s tyrosine kinase (BTK). BTK is a crucial enzyme in the signaling pathways of mast cells and basophils, immune cells central to the development of urticaria. By blocking BTK, remibrutinib effectively reduces the release of histamine and other inflammatory mediators, thereby mitigating the symptoms of CIndU. According to research detailed in the FDA label, remibrutinib similarly inhibits related kinases, tec protein tyrosine kinase (TEC) and BMX non-receptor tyrosine kinase (BMX), potentially contributing to its therapeutic effect.
Expanding Applications and Previous Approvals
The potential of remibrutinib extends beyond CIndU. The therapy is currently under clinical investigation for a range of other immune-mediated conditions, including chronic spontaneous urticaria (CSU), food allergy, and hidradenitis suppurativa. This broad exploration highlights Novartis’ commitment to leveraging the BTK inhibition pathway to address a diverse spectrum of immunological disorders. Notably, remibrutinib, marketed as Rhapsido®, already received FDA approval in September 2025 for the treatment of adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. This prior approval demonstrates the drug’s established safety and efficacy profile in a related urticarial condition.
Understanding Chronic Spontaneous Urticaria (CSU)
Chronic spontaneous urticaria, the condition for which remibrutinib is already approved, affects an estimated 1.7 million people in the United States. More than half of these individuals continue to experience symptoms despite increasing doses of antihistamines, highlighting the need for more effective treatment options. CSU is characterized by the spontaneous appearance of hives and itching, often lasting for more than six weeks. The underlying cause is often difficult to identify, and the condition can significantly impact a patient’s quality of life.
Looking Ahead
The successful RemIND trial and subsequent FDA submission represent a significant step forward in the management of chronic inducible urticaria. If approved for symptomatic dermographism, remibrutinib would offer a much-needed targeted therapy for patients who have not found adequate relief with existing treatments. The ongoing investigations into other immune-mediated conditions further underscore the potential of this novel BTK inhibitor to address a wide range of debilitating diseases. The next key milestone will be the FDA’s decision on the sNDA for symptomatic dermographism, anticipated in the coming months. Novartis will continue to analyze the full RemIND dataset and prepare for presentations at major medical conferences, further disseminating the findings to the global healthcare community.
The development of remibrutinib also reflects a broader trend in pharmaceutical research towards more targeted therapies that address the underlying mechanisms of disease. By specifically inhibiting BTK, remibrutinib offers a more precise approach compared to traditional treatments that often rely on broader immunosuppression. This targeted approach may lead to improved efficacy and a more favorable safety profile for patients.
What are your thoughts on this new treatment option? Share your comments below, and let’s continue the conversation about advancements in urticaria management.